The biotech sector in the US is flourishing. Leading biotech firms in the US are advancing cutting-edge technology to create treatments and cures for some of the deadliest diseases in the world. In this industry, household names include Celgene, Gilead Sciences, Abbott Laboratories, Merck & Co., and Biogen.
Biotech Companies In USA – List of Top Biotech Companies In USA
This list provides a thorough overview of the present state of biotech development in the US, from established biotechnology businesses to up-and-coming pharmaceutical behemoths. The biotechnology industry in America has expanded quickly in recent years, and these businesses are just a few instances of the cutting-edge steps being taken all around the country!
We’ve compiled some of the most intriguing businesses to keep an eye on in this blog. This list was created using our expertise of the market and is not ranked in any particular order, but it does contain both well-known start-ups and industry leaders.
Celgene
The development of novel therapies and cures for a variety of ailments is a top priority for biotech companies. Celgene is one of the top biotech firms in the United States. Celgene is a multinational biopharmaceutical business founded in 1986 that is committed to creating cutting-edge treatments to treat cancer and other severe diseases. Celgene is one of the biggest biotech companies in the USA, with more than 6,000 employees across the globe.
The company’s goods are sold in more than 70 nations, and it is well-established in Europe, US, and Asia. 2017 saw Bristol-Myers Squibb pay $74 billion to purchase Celgene. One of the biggest biotech companies in the world as a result. Celgene currently has a market valuation of more than $100 billion and is anticipated to produce revenue of $23 billion by 2022.
Gilead Sciences
Since its founding in 1987, Gilead Sciences has grown to become one of the industry’s top businesses. California’s Foster City serves as the company’s headquarters. The company’s goal is to discover, create, and market novel therapies that improve patient’s quality of life and length of life. A biopharmaceutical business called Gilead Sciences specializes in creating drugs to treat cancer, inflammation, liver conditions, and HIV/AIDS.
More than 11,000 people work for Gilead Sciences worldwide, and by 2022, it is anticipated that its revenue would total $41 billion. Treatments for cancer, hepatitis C, HIV, and other diseases are among the items offered by the company. For several years running, the business has held the top spot on the list of the best biotech firms in the USA.
Regeneron Pharmaceuticals
One of the most prosperous biotechnology companies in the United States was founded in 1988 and is called Regeneron Pharmaceuticals. The company’s headquarters are in Tarrytown, New York, and their predicted yearly income for 2022 is a staggering 21.58 billion US dollars, with a workforce size that has increased to 8,000 employees! High cholesterol, diabetes, and eye problems are just a few of the illnesses that Regeneron Pharmaceuticals focuses on treating.
The company is well-known for its several medications, including EYLEA, Praluent, Dupixent, Libtayo, etc., which are used to treat a number of conditions, including macular degeneration, high cholesterol, atopic dermatitis, and others. To create innovative goods and treatments, it works with numerous other businesses, including Bayer, Sanofi, Teva, and others.
Biogen
One of the top biotech firms in the US, Biogen focuses on creating drugs to treat autoimmune and neurological diseases. The business was established in 1978, and Cambridge, Massachusetts serves as its corporate headquarters. In 2022, Biogen is projected to earn around 22 billion USD in revenue.
Currently, the company employs about 7,500 employees. Tecfidera, which is used to treat multiple sclerosis, and Spinraza, which is used to treat spinal muscular atrophy, are examples of Biogen’s medicines. Additionally, Biogen is engaged in a number of clinical trials for potential novel therapies for the diseases Alzheimer’s, Parkinson’s, and Huntington’s.
Alexion Pharmaceuticals
Finding treatments and cures for some of the deadliest diseases is a top priority for biotech businesses. Alexion Pharmaceuticals is one of these businesses. Boston, Massachusetts-based Alexion is a multinational biopharmaceutical business that was established in 1992. The business generated $3.8 billion in revenue in 2018 and now employs more than 4,000 employees globally. By 2022, its revenue is anticipated to reach $17 billion. Serving patients with uncommon and ultra-rare conditions is Alexion’s mission.
The company currently has two experimental medicines in clinical testing and five approved pharmaceuticals on the market. Additionally, Alexion is developing a number of additional potential therapies for rare disorders. Alexion is positioned to have a huge effect because of its dedication to patients and track record of innovation.
Illumina Inc
Illumina Inc., one of the top biotechnology firms in the US, was founded in 1998. As of 2019, it had 14,000 workers and its headquarters were in San Diego, California. Its roots are deep in the American healthcare sector. The business creates and markets next-generation sequencing technology for the purpose of sequencing the human genome.
Sequencing by synthesis, sequencing by ligation, solid-state arrays, cluster formation tools, and reagents are only a few of Illumina’s offerings. The business generated a revenue of over $9.4 billion in 2018 and was ranked 140th out of 500 American firms on the Fortune 500 list. By 2022, Illumina’s revenue is anticipated to increase to almost 27 billion dollars.
Amgen
Amgen has made a name for itself in the biotech sector since its founding in 1980. The business is dedicated to developing and disseminating cutting-edge medicines for the treatment of life-threatening conditions like cancer, arthritis, and heart disease. It’s not surprising that Amgen is still one of the most important biotech businesses in America today given its more than 40 years of experience developing ground-breaking therapies.
Amgen is anticipated to produce $32 billion in revenue in 2022. The corporation has 21,000 employees and its headquarters are in Thousand Oaks, California. The product line of Amgen includes biological medicines for the management of a range of illnesses, including osteoporosis, cancer, and blood problems.
US Biotest
In 2002, US Biotech, a biotech business, was established. Jersey City, New Jersey serves as the location of the corporate headquarters. US Biotest concentrates on developing plasma-based solutions to find novel therapies, but it also offers support services for clinical trials.
The company’s revenue as of 2022 is $1.2 billion. The company employs almost 3,000 people. Therapeutic proteins, monoclonal antibodies, and vaccines are all included in the company’s product line. The company offers a wide variety of items and a robust product portfolio. The business is well-established in the US market and is predicted to expand quickly in the years to come.
Vertex Pharmaceuticals Inc
Joshua Boger and Kevin Kinsella launched Vertex Pharmaceuticals Inc. in 1989, making it one of the biotech companies in the USA. It is placed 137th on the Fortune 500 as of 2020 and possesses a market capitalization of $62.4 billion. In 2022, $13.3 billion in revenue is anticipated for the corporation. There are about 2,700 people working at Vertex worldwide, and its headquarters are in Boston, Massachusetts.
The company’s principal offerings include medicines for cancer, hepatitis C, and cystic fibrosis. The FDA authorized Kalydeco in 2012 for the treatment of cystic fibrosis, making it the company’s most renowned product.
Myriad Genetics
One of the leading biotech firms in the United States, Myriad Genetics has transformed the sector with its revolutionary solutions resulting from extensive research. They were established in 1991, and Salt Lake City, Utah, serves as their headquarters. Over 3 million tests are conducted annually by Myriad Genetics, which primarily focuses on delivering genetic testing services. Their sales were $842 million in 2019, and by 2022, it is anticipated to increase to $1.03 billion. They have 2,200 employees as of 2018.
